Fixed long-acting combinations of both anticholinergic and beta-agonist bronchodilators, not previously available, have been developed. A new fixed combination of glycopyrronium and indacaterol has ...
Treatment is therefore directed toward relief of symptoms and a reduction in the incidence of acute exacerbations. Within the past decade, major advances in management have been made in the ...
A study of older patients with chronic obstructive pulmonary disease (COPD) suggests that new use of the long-acting bronchodilators β-agonists and anticholinergics was associated with similar ...
LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global bronchodilators market is expected to grow at a CAGR of close to 5% during the forecast period. This ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
Portland, OR, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Bronchodilators Market by Drug class (Sympathomimetics, Anticholinergics, Phosphodiesterase ...
Dr. Wasserman answers the question: 'Standard Treatment Strategy For Asthma?' — -- Question: What is the standard treatment strategy for asthma? Answer: The standard treatment of asthma is to ...
A study of older patients with chronic obstructive pulmonary disease (COPD) suggests that new use of the long-acting bronchodilators β-agonists and anticholinergics was associated with similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback